Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib alone or with atezolizumab in advanced solid tumors
NL-OMON50370Phase 1Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabozantinib and atezolizumab in Nonhematologic neoplasms, renal cell carcinoma (RCC), transitional cell carcinoma (TCC) and 12 more (6 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum tolerated dose and Objective response rate by RECIST 1.1. Started Sep 2018; status: active, not recruiting.
02
Drugs
cabozantinibatezolizumab
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)transitional cell carcinoma (TCC)prostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50370.